Evidence map›Paper›PMID 31773467›Full record

ArticleMolecular and cellular biochemistry2020

Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Aymen Shatnawi, Sridhar A Malkaram, Tamer Fandy, Efrosini Tsouko

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Aymen ShatnawiDepartment of Pharmaceutical and Administrative Sciences, University of Charleston School of Pharmacy, 2300 MacCorkle Ave SE, Charleston, WV, 25304, USA. aymenshatnawi@ucwv.edu.ORCID http://orcid.org/0000-0001-6435-3727
Sridhar A MalkaramDepartment of Mathematics and Computer Sciences, West Virginia State University, W729, Wallace Hall, Institute, WV, 25112, USA.
Tamer FandyDepartment of Pharmaceutical and Administrative Sciences, University of Charleston School of Pharmacy, 2300 MacCorkle Ave SE, Charleston, WV, 25304, USA.
Efrosini TsoukoDepartment of Orthopedic Surgery, Baylor College of Medicine, Houston, TX, 77030, USA.
University of Charleston · USBaylor College of Medicine · USWest Virginia State University · US

Funding

WV-IDeA Network of Biomedical Research Excellence (US) P20GM103434
6 · The paper itself

Abstract

INhibitor of Growth protein 4 (ING4) is a potential chromatin modifier that has been implicated in several cancer-related processes. However, the role of ING4 in prostate cancer (PC) is largely unknown. This study aimed to assess ING4's role in global transcriptional regulation in PC cells to identify potential cellular processes associated with ING4 loss. RNA-Seq using next-generation sequencing (NGS) was used to identify altered genes in LNCaP PC cells following ING4 depletion. Ingenuity pathways analysis (IPA

Indexed as

Gene Expression Regulation, NeoplasticCell Cycle ProteinsCell Line, TumorHomeodomain ProteinsHumansMaleProstatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionTumor Suppressor ProteinsCell Cycle ProteinsHomeodomain ProteinsING4 protein, humanTumor Suppressor ProteinsGene expressionING4Ingenuity pathways analysisProstate cancerRNA-Seq

Identifiers

PMID31773467
OpenAlexW2991244614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.